C-SSKLRejuvenate Bio
gene therapy, FGF21, partial reprogramming
reprogramminggene therapy
Loading
Загрузка раздела...0-100 chain-logic scale · 15 dimensions · scored on public evidence
All companiesC-SSKL
C-SSKLC-SSKLgene therapy, FGF21, partial reprogramming
0-100 chain-logic scale · 15 dimensions · scored on public evidence
Rejuvenate Bio gene therapy, FGF21, partial reprogramming
Rejuvenate Bio разрабатывает новые методы терапии для лечения старения и возрастных заболеваний с помощью таргетной генной терапии. Компания была создана на базе лаборатории George Church в Harvard Medical School и Wyss Institute. На ее сайте описывается работа в области здоровья человека и животных, включая направленную на печень генную терапию, FGF21, сердечные и метаболические заболевания, а также возрастные заболевания у собак.
The published score reflects a curated read of public evidence across 16 dimensions. Each dimension below shows the rationale we used. Disagree with a reading? Tell us where we are wrong
Higher up = higher Eternal Search score. Further right = closer to achieving real longevity outcomes (early mechanism → translational → near-term readout). Bubble size = capital deployed. Watch for MISMATCHES: big bubbles on the left are well-capitalized but far from goals; small bubbles on the right are doing more with less.
Rejuvenate Bio — Early mechanism · Lower middle. Derived deterministically from 22 extracted project(s). Most-advanced status: preclinical. Band: early_mechanism. Modifiers: +5 depth (15 programs at preclinical).…
Source: Deterministic